These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 32599694)

  • 1. NCI-Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center.
    Kim DJ; Otap D; Ruel N; Gupta N; Khan N; Dorff T
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience.
    McCaskill-Stevens W; McKinney MM; Whitman CG; Minasian LM
    J Clin Oncol; 2005 Aug; 23(22):5247-54. PubMed ID: 16051967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic proximity and racial disparities in cancer clinical trial participation.
    Kanarek NF; Tsai HL; Metzger-Gaud S; Damron D; Guseynova A; Klamerus JF; Rudin CM
    J Natl Compr Canc Netw; 2010 Dec; 8(12):1343-51. PubMed ID: 21147901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.
    Kaluzny A; Brawley O; Garson-Angert D; Shaw J; Godley P; Warnecke R; Ford L
    J Natl Cancer Inst; 1993 Dec; 85(23):1945-50. PubMed ID: 8230286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.
    Kunos CA; Massett HA; Galassi A; Walker JL; Good MJ; Díaz LB; McCaskill-Stevens W
    Front Oncol; 2018; 8():102. PubMed ID: 29692980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
    J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.
    Hirsch BR; Locke SC; Abernethy AP
    J Oncol Pract; 2016 Apr; 12(4):e350-8. PubMed ID: 27026649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials.
    Regnante JM; Richie N; Fashoyin-Aje L; Hall LL; Highsmith Q; Louis J; Turner K; Hoover S; Lee SC; González E; Williams E; Adams H; Obasaju C; Sargeant I; Spinner J; Reddick C; Gandee M; Geday M; Dang J; Watson R; Chen MS
    Contemp Clin Trials Commun; 2020 Mar; 17():100532. PubMed ID: 32055746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
    Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
    WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding access to early phase trials: the CATCH-UP.2020 experience.
    Baranda JC; Diaz FJ; Rubinstein L; Shields AF; Dayyani F; Mehta A; Mehnert JM; Trent J; Mabaera R; Mooney M; Moscow JA; Doroshow J; Waters B; Ivy P; Gore SD; Thomas A
    JNCI Cancer Spectr; 2023 Jan; 7(1):. PubMed ID: 36525371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee.
    Newman LA; Lee CT; Parekh LP; Stewart AK; Thomas CR; Beltran RA; Lucci A; Green B; Ota D; Nelson H;
    Cancer; 2006 Jan; 106(1):188-95. PubMed ID: 16333856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.
    Peterson JS; Plana D; Bitterman DS; Johnson SB; Aerts HJWL; Kann BH
    Cancer Med; 2023 Feb; 12(4):4715-4724. PubMed ID: 36398619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Cancer Institute's Cancer Disparities Research Partnership Program: Experience and Lessons Learned.
    Wong RS; Vikram B; Govern FS; Petereit DG; Maguire PD; Clarkson MR; Heron DE; Coleman CN
    Front Oncol; 2014; 4():303. PubMed ID: 25405101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center.
    Iruku P; Goros M; Gelfond J; Chang J; Padalecki S; Mesa R; Kaklamani VG
    Contemp Clin Trials Commun; 2019 Sep; 15():100421. PubMed ID: 31372575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
    Paul K; Sathianathen N; Dahm P; Le C; Konety BR
    J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.